Inhibition of DYRK1A stimulates human β-cell proliferation

Ercument Dirice, Deepika Walpita, Amedeo Vetere, Bennett C. Meier, Sevim Kahraman, Jiang Hu, Vlado Dančík, Sean M. Burns, Tamara J. Gilbert, David Olson, Paul A. Clemons, Rohit N. Kulkarni, Bridget K. Wagner

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1). While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4). Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo. Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment. Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) and cell division cycle-like kinase families. Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling. Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle-related genes, suggesting that true proliferation is induced by 5-IT. Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice. These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.

Original languageEnglish (US)
Pages (from-to)1660-1671
Number of pages12
JournalDiabetes
Volume65
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Cell Proliferation
Type 1 Diabetes Mellitus
Rodentia
Harmine
Adenosine Kinase
NFATC Transcription Factors
cdc Genes
Gene Expression Profiling
Tacrolimus
5-iodotubercidin
Biological Products
Type 2 Diabetes Mellitus
Capsules
Cell Cycle
Phosphotransferases
Swine
Insulin
Kidney
Glucose
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Dirice, E., Walpita, D., Vetere, A., Meier, B. C., Kahraman, S., Hu, J., ... Wagner, B. K. (2016). Inhibition of DYRK1A stimulates human β-cell proliferation. Diabetes, 65(6), 1660-1671. https://doi.org/10.2337/db15-1127

Inhibition of DYRK1A stimulates human β-cell proliferation. / Dirice, Ercument; Walpita, Deepika; Vetere, Amedeo; Meier, Bennett C.; Kahraman, Sevim; Hu, Jiang; Dančík, Vlado; Burns, Sean M.; Gilbert, Tamara J.; Olson, David; Clemons, Paul A.; Kulkarni, Rohit N.; Wagner, Bridget K.

In: Diabetes, Vol. 65, No. 6, 01.06.2016, p. 1660-1671.

Research output: Contribution to journalArticle

Dirice, E, Walpita, D, Vetere, A, Meier, BC, Kahraman, S, Hu, J, Dančík, V, Burns, SM, Gilbert, TJ, Olson, D, Clemons, PA, Kulkarni, RN & Wagner, BK 2016, 'Inhibition of DYRK1A stimulates human β-cell proliferation', Diabetes, vol. 65, no. 6, pp. 1660-1671. https://doi.org/10.2337/db15-1127
Dirice E, Walpita D, Vetere A, Meier BC, Kahraman S, Hu J et al. Inhibition of DYRK1A stimulates human β-cell proliferation. Diabetes. 2016 Jun 1;65(6):1660-1671. https://doi.org/10.2337/db15-1127
Dirice, Ercument ; Walpita, Deepika ; Vetere, Amedeo ; Meier, Bennett C. ; Kahraman, Sevim ; Hu, Jiang ; Dančík, Vlado ; Burns, Sean M. ; Gilbert, Tamara J. ; Olson, David ; Clemons, Paul A. ; Kulkarni, Rohit N. ; Wagner, Bridget K. / Inhibition of DYRK1A stimulates human β-cell proliferation. In: Diabetes. 2016 ; Vol. 65, No. 6. pp. 1660-1671.
@article{c0f621f3eee7477db1346ae4924bb9ae,
title = "Inhibition of DYRK1A stimulates human β-cell proliferation",
abstract = "Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1). While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4). Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo. Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment. Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) and cell division cycle-like kinase families. Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling. Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle-related genes, suggesting that true proliferation is induced by 5-IT. Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice. These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.",
author = "Ercument Dirice and Deepika Walpita and Amedeo Vetere and Meier, {Bennett C.} and Sevim Kahraman and Jiang Hu and Vlado Danč{\'i}k and Burns, {Sean M.} and Gilbert, {Tamara J.} and David Olson and Clemons, {Paul A.} and Kulkarni, {Rohit N.} and Wagner, {Bridget K.}",
year = "2016",
month = "6",
day = "1",
doi = "10.2337/db15-1127",
language = "English (US)",
volume = "65",
pages = "1660--1671",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Inhibition of DYRK1A stimulates human β-cell proliferation

AU - Dirice, Ercument

AU - Walpita, Deepika

AU - Vetere, Amedeo

AU - Meier, Bennett C.

AU - Kahraman, Sevim

AU - Hu, Jiang

AU - Dančík, Vlado

AU - Burns, Sean M.

AU - Gilbert, Tamara J.

AU - Olson, David

AU - Clemons, Paul A.

AU - Kulkarni, Rohit N.

AU - Wagner, Bridget K.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1). While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4). Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo. Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment. Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) and cell division cycle-like kinase families. Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling. Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle-related genes, suggesting that true proliferation is induced by 5-IT. Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice. These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.

AB - Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1). While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4). Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo. Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment. Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) and cell division cycle-like kinase families. Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling. Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle-related genes, suggesting that true proliferation is induced by 5-IT. Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice. These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.

UR - http://www.scopus.com/inward/record.url?scp=84969849459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969849459&partnerID=8YFLogxK

U2 - 10.2337/db15-1127

DO - 10.2337/db15-1127

M3 - Article

VL - 65

SP - 1660

EP - 1671

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 6

ER -